Dilip Shanghvi-led Sun Pharma's most expensive M&A deal signals fading allure of US generics business
Summary
Sun Pharma's $11.75 billion buyout of Organon signifies a strategic shift from focusing on the US generics market to seeking geographic diversification as an an...
Description
Sun Pharma's $11.75 billion buyout of Organon signifies a strategic shift from focusing on the US generics market to seeking geographic diversification as an an...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source